NCT06464133
Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis
Enrolling by Invitation
Not specifiedAll AgesObservationalUniversity of PennsylvaniaInvestigator-initiated
~300 participants
Updated 2026-04-24 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To identify and describe Filaggrin (FLG) loss of function (LOF) variants in the GAD-L cohort using a high-throughput PCR approach that incorporates Fluidigm microfluidics technology and next-generation sequencing (NGS) to sequence the entire FLG gene.
Measured over 2 year data/sample collection period - cross-sectional cohort study of patients with a diagnosis of atopic dermatitis
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Established diagnosis of AD based on physician report of at least one-year duration
Self-identification as Latino/Latinx or Hispanic
What this trial measures
- To identify and describe Filaggrin (FLG) loss of function (LOF) variants in the GAD-L cohort using a high-throughput PCR approach that incorporates Fluidigm microfluidics technology and next-generation sequencing (NGS) to sequence the entire FLG gene.2 year data/sample collection period - cross-sectional cohort study of patients with a diagnosis of atopic dermatitis